You searched for "surgical"
BPH therapy: how to find one’s way through the maze?
This communication is from the Young Academic Urologists (YAU) group of the European Association of Urologists (EAU). A purpose-built questionnaire of current practice was sent to 2000 members, of which 637 responded (68% were aged 50 or younger). Alpha blockers...Bladder cancer – an overshadowed ‘volcano’
Bladder cancer has often been overshadowed by the limelight of prostate cancer. However, of all the urological cancers, bladder cancer is the only one which has shown a slight decline in age-standardised five-year survival rates over the last couple of...COVID-19: the impact on urology so far
“How very little can be done under the spirit of fear.” Florence Nightingale Since 31 December 2019 when a cluster of pneumonia cases with an unknown cause were first referred to the WHO Country Office in China, there has been...
Robot assisted laparoscopic prostatectomy versus open retropubic prostatectomy – complication and readmission rates
Readmission rates in postoperative patients are an important health economic and clinical challenge faced in the modern NHS, with financial levies attached. In America since 2013, hospitals have been faced with ‘readmission penalties’ deducted from Medicare reimbursements. This was the...Penile cancer: a practical approach
Penile cancer is rare and accounts for less than 1% of all new cancer cases in males in the UK, with around 640 new cases diagnosed every year [1]. In England and Wales, the annual incidence is between 1.2 and...
Intermittent vs. continuous hormonal therapy for metastatic prostate cancer
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy
There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...
